Sema prices are all over the place — Q2 2026 vendor pricing roundup

Taking the question as asked, rather than the general version of it. The pattern that distinguishes a bad batch from an exit is behaviour rather than product. A bad batch comes with communication, a reshipment offer and a batch number. An exit comes with slower replies, pressure toward less reversible payment methods, sudden discounting, and the same reassurance repeated without any new information. The product tells you less than the correspondence does.

LarryQC_SD said:

The pattern that distinguishes a bad batch from an exit is behaviour rather than product.

Agreed, with a caveat about community reputation: it is a lagging indicator. Reports arrive weeks after orders, so a supplier can look excellent for a month after quality has already changed.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

PharmHunterJen said:

Denied on prior authorisation twice, approved on the third attempt after a peer-to-peer, and the only thing that changed was who was doing the…

Right, and one flattering data point from a group buy is not consistency. Consistency means separate batches, separately commissioned, over months.

Clinical perspective, offered as context rather than as advice.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.